- Kytopen and Excellos are exploring a collaboration to assess the compatibility of the Flowfect Tx® platform with Excellos’ donor-to-dose manufacturing model.
- The initiative aims to identify opportunities to improve consistency, scalability, and cell quality in next-generation cell therapy development.
Kytopen Corp., a company focused on continuous flow cellular engineering, has announced that it is exploring a collaboration with Excellos, a cell therapy CDMO and member of Blood Centers of America, to advance non-viral cell therapy manufacturing technologies. The work will centre on evaluating the compatibility of the Flowfect Tx® platform with Excellos’ integrated manufacturing and cell characterisation capabilities.
The companies intend to assess how their combined technologies may enhance process consistency, scalability, and overall cell quality in the development of advanced cell-based therapies. Both organisations state that they share a commitment to translating scientific innovation into patient-centred manufacturing solutions.
“Kytopen’s Flowfect® technology represents an exciting advancement in non-viral cellular engineering, and we’re eager to explore how it could complement our donor-to-dose expertise.”
Tom VanCott, chief executive officer of Excellos
Kevin Gutshall, chief commercial officer at Kytopen, added that Excellos’ expertise positions them as an ideal partner to demonstrate the potential of the Flowfect Tx® GMP platform.
The initial phase of the initiative will focus on identifying scientific and operational synergies, with the possibility of further collaboration as development priorities align. The companies expect these proof-of-principle efforts to inform understanding of biological and process complexities in emerging cell therapy manufacturing workflows.
